Working on neuro inflammatory research for Fibromyalgia at Stamford University Dr Jarred Younger trialled Low-Dose Naltrexone ncbi.nlm.nih.gov/pmc/articl... .The information gained suggested further research that also included the ME/CFS population would be useful in understanding the effectiveness as a treatment cortjohnson.org/blog/2015/0...
The possible benefits of down regulating the micrglia in the brain while understanding the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically (off-label) to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.
LDN causes a compensatory increase in an endogenous opioid, the opioid growth factor this short term blockade of the opioid receptors provided a breakthrough in auto immune conditions that were not down regulating the inflammatory response.
Naltrexone was designed for opiate addicts using around 50 -100mg doses, the use use off label at 1.5 - 4.5mg treating cancer pain and HIV/AIDS this of label use is not researched by the drugs companies as any money possible has already been made, hence a low cost for medication under £1 per day.
More information at ldnnow.co.uk/